Answers are grounded in this paper and cite their sources.
The fi ndings in this report show safety, pharmacokinetics, RNAi mechanism of action, and clinical activity with a novel fi rst-in-class LNP-formulated RNAi therapeutic in patients with cancer. The ability to harness RNAi to facilitate specifi c multitargeting, as well as increase the number of druggable targets, has important implications for future drug development in oncology.
No takes yet. Share an insight, caveat, or question.
Tabernero et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: